Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.
Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients
Sponsor: New York State Psychiatric Institute
Listed as NCT02255357, this PHASE2/PHASE3 trial focuses on Cocaine Dependence and remains completed. Sponsored by New York State Psychiatric Institute, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2023 — Jul 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Nov 2018 — Dec 2019 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .